Characterization of the Structural Features and Interactions of Sclerostin
暂无分享,去创建一个
P. Slocombe | M. Carr | F. Muskett | V. Veverka | M. Robinson | Richard J. Taylor | A. Ventom | B. Mulloy | Li Zhang | Jianhua Gong | C. Pászty | A. Henry | A. Moore | K. Greenslade | M. Muzylak | X. Qian
[1] P. Kostenuik,et al. Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] M. Forster,et al. Application of drug discovery software to the identification of heparin-binding sites on protein surfaces: a computational survey of the 4-helix cytokines , 2008 .
[3] M. Carr,et al. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR , 2008, Oncogene.
[4] M. Yavropoulou,et al. The role of the Wnt signaling pathway in osteoblast commitment and differentiation. , 2007, Hormones.
[5] P. T. Choong,et al. Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A , 2007, Oncogene.
[6] Mark L. Johnson,et al. The Wnt signaling pathway and bone metabolism , 2007, Current opinion in rheumatology.
[7] Xi He,et al. LRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST* , 2006, Journal of Biological Chemistry.
[8] Hans Clevers,et al. Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.
[9] Scott Saunders,et al. Bone Density Ligand, Sclerostin, Directly Interacts With LRP5 but Not LRP5G171V to Modulate Wnt Activity , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] H. Vrieling,et al. Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP‐Stimulated Bone Formation , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] V. Nurcombe,et al. Coordinated fibroblast growth factor and heparan sulfate regulation of osteogenesis. , 2006, Gene.
[12] Sabrina Cattaruzza,et al. Approaching the proteoglycome: molecular interactions of proteoglycans and their functional output. , 2006, Macromolecular bioscience.
[13] M. Forster,et al. Computational approaches to the identification of heparin-binding sites on the surfaces of proteins. , 2006, Biochemical Society transactions.
[14] K. Garcia,et al. Structure of artemin complexed with its receptor GFRalpha3: convergent recognition of glial cell line-derived neurotrophic factors. , 2006, Structure.
[15] C. Robinson,et al. Structural basis for the inhibition of activin signalling by follistatin , 2006, The EMBO journal.
[16] M. Carr,et al. NMR Assignment and Secondary Structure Determination of the C-terminal MA-3 Domain of the Tumour Suppressor Protein Pdcd4 , 2006, Journal of Biomolecular NMR.
[17] M. Carr,et al. NMR Assignment of the mTOR Domain Responsible for Rapamycin Binding , 2006, Journal of biomolecular NMR.
[18] J. Reeve,et al. The FASEB Journal express article 10.1096/fj.05-4221fje. Published online August 25, 2005. ©2005 FASEB , 2022 .
[19] Xi He,et al. SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor* , 2005, Journal of Biological Chemistry.
[20] Peng Liu,et al. Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling* , 2005, Journal of Biological Chemistry.
[21] H. Schreuder,et al. Crystal structure of recombinant human growth and differentiation factor 5: evidence for interaction of the type I and type II receptor-binding sites. , 2005, Biochemical and biophysical research communications.
[22] Wayne A. Hendrickson,et al. Structure of human follicle-stimulating hormone in complex with its receptor , 2005, Nature.
[23] Xinhua Lin,et al. Functions of heparan sulfate proteoglycans in cell signaling during development , 2004, Development.
[24] J. Latham,et al. Noggin and Sclerostin Bone Morphogenetic Protein Antagonists Form a Mutually Inhibitory Complex* , 2004, Journal of Biological Chemistry.
[25] M. Karperien,et al. Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist , 2004, The Journal of experimental medicine.
[26] Geoffrey J. Barton,et al. The Jalview Java alignment editor , 2004, Bioinform..
[27] John A Latham,et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist , 2003, The EMBO journal.
[28] Nobuyuki Itoh,et al. Sclerostin Is a Novel Secreted Osteoclast-derived Bone Morphogenetic Protein Antagonist with Unique Ligand Specificity* , 2003, Journal of Biological Chemistry.
[29] Ajamete Kaykas,et al. Zebrafish Prickle, a Modulator of Noncanonical Wnt/Fz Signaling, Regulates Gastrulation Movements , 2003, Current Biology.
[30] P. Beighton,et al. The natural history of sclerosteosis , 2003, Clinical genetics.
[31] Jens Bollerslev,et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. , 2003, American journal of human genetics.
[32] C. Dominguez,et al. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. , 2003, Journal of the American Chemical Society.
[33] Markus Affolter,et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin , 2002, Nature.
[34] Torsten Herrmann,et al. Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. , 2002, Journal of molecular biology.
[35] R. Kelley,et al. IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor binding , 2001, The EMBO journal.
[36] M Dioszegi,et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.
[37] D. Galas,et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. , 2001, American journal of human genetics.
[38] R. Fletterick,et al. Crystal structure of neurotrophin-3 homodimer shows distinct regions are used to bind its receptors. , 1998, Biochemistry.
[39] R. Williamson,et al. High Resolution Structure of the N-terminal Domain of Tissue Inhibitor of Metalloproteinases-2 and Characterization of Its Interaction Site with Matrix Metalloproteinase-3* , 1998, The Journal of Biological Chemistry.
[40] R. Williamson,et al. Mapping the binding site for matrix metalloproteinase on the N-terminal domain of the tissue inhibitor of metalloproteinases-2 by NMR chemical shift perturbation. , 1997, Biochemistry.
[41] A. D. de Vos,et al. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[42] Charles Eigenbrot,et al. X-ray structure of glial cell-derived neurotrophic factor at 1.9 Å resolution and implications for receptor binding , 1997, Nature Structural Biology.
[43] R. Wait,et al. Molecular Weight Measurements of Low Molecular Weight Heparins by Gel Permeation Chromatography , 1997, Thrombosis and Haemostasis.
[44] R. Huber,et al. Crystal structure of a coagulogen, the clotting protein from horseshoe crab: a structural homologue of nerve growth factor. , 1996, The EMBO journal.
[45] K. Constantine,et al. Localizing the NADP+ binding site on the MurB enzyme by NMR , 1996, Nature Structural Biology.
[46] J. Schrader,et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[47] D. M. F. Aalten,et al. PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules , 1996, J. Comput. Aided Mol. Des..
[48] M. Billeter,et al. MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.
[49] D. Stuart,et al. Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer. , 1995, Biochemistry.
[50] W A Hendrickson,et al. Structure of human chorionic gonadotropin at 2.6 A resolution from MAD analysis of the selenomethionyl protein. , 1994, Structure.
[51] C. Sander,et al. Protein structure comparison by alignment of distance matrices. , 1993, Journal of molecular biology.
[52] M. Forster,et al. N.m.r. and molecular-modelling studies of the solution conformation of heparin. , 1993, The Biochemical journal.
[53] W. Hendrickson,et al. A structural superfamily of growth factors containing a cystine knot motif , 1993, Cell.
[54] F. Winkler,et al. Crystal structure of human platelet‐derived growth factor BB. , 1992, The EMBO journal.
[55] M. Grütter,et al. An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth fact or-β2 , 1992, Nature.
[56] K Wüthrich,et al. Improved efficiency of protein structure calculations from NMR data using the program DIANA with redundant dihedral angle constraints , 1991, Journal of biomolecular NMR.
[57] O. Avsian-Kretchmer,et al. Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. , 2004, Molecular endocrinology.
[58] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[59] G J Kleywegt,et al. Model building and refinement practice. , 1997, Methods in enzymology.